Literature DB >> 9337061

CD34 counts to predict the adequate collection of peripheral blood progenitor cells.

S Armitage1, R Hargreaves, D Samson, M Brennan, E Kanfer, C Navarrete.   

Abstract

An essential prerequisite for successful procurement of sufficient autologous peripheral blood progenitor cells (PBPC) for engraftment is the optimal timing of collection. A number of surrogate markers of peripheral blood progenitor cells were analysed to identify a single test which could predict the optimum time to harvest, providing at least 2 x 10(6) CD34+ cells/kg patient body weight. The study comprised 95 patients undergoing varied mobilisation regimens with chemotherapy and G-CSF for both solid tumours and haematological malignancies. One hundred and fifty-seven PBPC harvests were collected. Full blood counts (FBC) and CD34+ cell enumeration was performed on blood samples taken during the mobilisation period and immediately prior to leucapheresis (pre-harvest). All PBPC collections were assayed for colony-forming cells and CD34+ cells in addition to a FBC. The white cell count on the day of harvest showed only weak correlation with the total number of CD34+ cells in the collection (r = 0.30). In contrast, the absolute number of circulating CD34+ cells strongly correlated with the CD34+ cell and CFU-GM yield of the corresponding apheresis product. Provided the mobilisation sample contained > or =20 x 10(6) CD34+ cells/ml, 94% of single collections, performed the following day, contained > or =2 x 10(6) CD34+ cells/kg.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337061     DOI: 10.1038/sj.bmt.1700938

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with β-thalassemia major.

Authors:  Varnavas C Constantinou; Asimina Bouinta; Garyfalia Karponi; Fani Zervou; Penelope-Georgia Papayanni; George Stamatoyannopoulos; Achilles Anagnostopoulos; Evangelia Yannaki
Journal:  Transfusion       Date:  2016-12-17       Impact factor: 3.157

2.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

3.  Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections.

Authors:  Ellinor I Peerschke; Christine Moung; Melissa S Pessin; Peter Maslak
Journal:  Transfusion       Date:  2015-03-21       Impact factor: 3.157

Review 4.  Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update.

Authors:  Yavuz M Bilgin
Journal:  J Blood Med       Date:  2021-06-02

5.  Effects of intravenous human umbilical cord blood CD34+ stem cell therapy versus levodopa in experimentally induced Parkinsonism in mice.

Authors:  Noha Abo-Grisha; Soha Essawy; Dina M Abo-Elmatty; Zenab Abdel-Hady
Journal:  Arch Med Sci       Date:  2013-11-29       Impact factor: 3.318

6.  High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.

Authors:  Jin Seok Ahn; Seonyang Park; Seock-Ah Im; Sung-Soo Yoon; Jong-Seok Lee; Byoung Kook Kim; Soo-Mee Bang; Eun Kyung Cho; Jae Hoon Lee; Chul Won Jung; Hugh Chul Kim; Chu Myung Seong; Moon Hee Lee; Chul Soo Kim; Keun Seok Lee; Jung Ae Lee; Myung-Ju Ahn
Journal:  Korean J Intern Med       Date:  2005-09       Impact factor: 2.884

7.  Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.

Authors:  Jeremy Pantin; Enkhtsetseg Purev; Xin Tian; Lisa Cook; Theresa Donohue-Jerussi; Elena Cho; Robert Reger; Matthew Hsieh; Hanh Khuu; Gary Calandra; Nancy L Geller; Richard W Childs
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

8.  Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.

Authors:  Fan Yang; Daopei Lu; Yu Hu; Xiaojun Huang; He Huang; Jing Chen; Depei Wu; Jianmin Wang; Chun Wang; Mingzhe Han; Hu Chen
Journal:  Ann Transplant       Date:  2017-06-27       Impact factor: 1.530

9.  [Consensus of Chinese experts on the mobilization and collection of autologous hematopoietic stem cells in lymphoma (2020)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-12-14

Review 10.  Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?

Authors:  Whitney D Wallis; Muzaffar H Qazilbash
Journal:  World J Transplant       Date:  2017-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.